Shares of Ashtead Group plc (LON:AHT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is GBX 5,537.86 ($71.82).
A number of brokerages have recently issued reports on AHT. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 6,500 ($84.30) price objective on shares of Ashtead Group in a report on Wednesday, September 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 6,150 ($79.76) price objective on shares of Ashtead Group in a research note on Tuesday, September 3rd. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 7,000 ($90.78) price target on shares of Ashtead Group in a research report on Monday, October 14th.
View Our Latest Analysis on AHT
Ashtead Group Trading Down 0.4 %
Insider Buying and Selling
In other Ashtead Group news, insider Lucinda Riches sold 1,000 shares of the company’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of GBX 5,880 ($76.25), for a total value of £58,800 ($76,254.70). 0.64% of the stock is currently owned by corporate insiders.
Ashtead Group Company Profile
Ashtead Group plc, together with its subsidiaries, engages in the construction, industrial, and general equipment rental business in the United States, the United Kingdom, and Canada. It provides pumps, power generation, heating, cooling, scaffolding, traffic management, temporary flooring, trench shoring, and lifting services.
Recommended Stories
- Five stocks we like better than Ashtead Group
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Intel: Is Now the Time to Be Brave?
- Why Invest in 5G? How to Invest in 5G Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Investing in the High PE Growth Stocks
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Ashtead Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ashtead Group and related companies with MarketBeat.com's FREE daily email newsletter.